Bioventure, Minapharm Pharmaceuticals and MiGenTra sign exclusive agreement for commercialization of multiple biosimilar candidates of Alvotech in the MENA
Bioventure, a Dubai-based pharmaceutical company, Minapharm Pharmaceuticals, a Cairo-based pharmaceutical company, and MiGenTra, a Berlin-based pharmaceutical company, have signed an exclusive license agreement for the commercialization of multiple biosimilar candidates developed and manufactured by Alvotech, in Egypt and eighteen additional countries in Africa and the Middle East.